LifeStance Health Group (NASDAQ:LFST) Earns Overweight Rating from Analysts at KeyCorp

KeyCorp began coverage on shares of LifeStance Health Group (NASDAQ:LFST) in a research note published on Tuesday, MarketBeat.com reports. The brokerage issued an overweight rating and a $9.00 price target on the stock.

A number of other analysts have also weighed in on LFST. Canaccord Genuity Group initiated coverage on shares of LifeStance Health Group in a research note on Thursday, April 3rd. They issued a “buy” rating and a $8.00 price objective for the company. The Goldman Sachs Group raised shares of LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a research report on Monday, December 16th. Finally, William Blair reissued an “outperform” rating on shares of LifeStance Health Group in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.58.

LifeStance Health Group Price Performance

Shares of LFST stock opened at $6.77 on Tuesday. LifeStance Health Group has a twelve month low of $4.64 and a twelve month high of $8.61. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.19. The stock has a fifty day simple moving average of $7.30 and a two-hundred day simple moving average of $7.33. The stock has a market capitalization of $2.60 billion, a price-to-earnings ratio of -26.04 and a beta of 1.30.

Insider Activity

In related news, insider Lisa K. Miller sold 18,845 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.90, for a total transaction of $130,030.50. Following the completion of the transaction, the insider now owns 339,810 shares in the company, valued at $2,344,689. The trade was a 5.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 6.60% of the company’s stock.

Hedge Funds Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently bought and sold shares of the company. Summit Global Investments acquired a new stake in shares of LifeStance Health Group in the 1st quarter worth $241,000. Wellington Management Group LLP raised its stake in LifeStance Health Group by 9.2% in the fourth quarter. Wellington Management Group LLP now owns 5,276,237 shares of the company’s stock valued at $38,886,000 after buying an additional 445,796 shares during the last quarter. Forum Financial Management LP acquired a new stake in LifeStance Health Group in the fourth quarter worth about $110,000. Neo Ivy Capital Management grew its stake in shares of LifeStance Health Group by 26,132.3% during the fourth quarter. Neo Ivy Capital Management now owns 182,052 shares of the company’s stock worth $1,341,000 after acquiring an additional 181,358 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of LifeStance Health Group by 16.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 604,321 shares of the company’s stock valued at $4,454,000 after acquiring an additional 87,502 shares in the last quarter. 85.50% of the stock is owned by hedge funds and other institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.